PI(3)K–Akt–mTOR pathway as a potential therapeutic target in neuroendocrine tumors

2008 ◽  
Vol 3 (2) ◽  
pp. 207-222 ◽  
Author(s):  
Kathrin Zitzmann ◽  
George Vlotides ◽  
Burkhard Göke ◽  
Christoph J Auernhammer
Keyword(s):  
Neuroendocrine Tumors ◽  
Therapeutic Target ◽  
Mtor Pathway ◽  
Potential Therapeutic Target

scholarly journals The Akt/mTOR pathway in cancer stem/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma

Oncotarget ◽  
2018 ◽  
Vol 9 (71) ◽  
pp. 33549-33561 ◽  
Author(s):  
Hisham F. Bahmad ◽  
Tarek H. Mouhieddine ◽  
Reda M. Chalhoub ◽  
Sahar Assi ◽  
Tarek Araji ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Therapeutic Target ◽  
Mtor Pathway ◽  
Potential Therapeutic Target

scholarly journals Global methylation-demethylation status in pituitary neuroendocrine tumors as potential therapeutic target

2020 ◽  
Author(s):  
Borbála Szabó ◽  
Kinga Németh ◽  
Katalin Mészáros ◽  
Nikolette Szücs ◽  
Sándor Czirják ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
Global Methylation

The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy

2019 ◽  
Vol 24 (39) ◽  
pp. 4646-4651 ◽  
Author(s):  
Seyed A. Javadinia ◽  
Soodabeh Shahidsales ◽  
Azar Fanipakdel ◽  
Asma Mostafapour ◽  
Mona Joudi-Mashhad ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cross Talk ◽  
Therapeutic Target ◽  
Cell Biology ◽  
Current Knowledge ◽  
Mammalian Target Of Rapamycin ◽  
Mtor Pathway ◽  
Mtor Signaling ◽  
Phosphatidylinositol 3 Kinase ◽  
Potential Therapeutic Target

The Phosphatidylinositol 3-kinase/AKT/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) pathway has a critical regulatory role in cell biology including translation, transcription, and autophagy. Dysregulation of this pathway is involved in the pathogenesis, development, and prognosis of esophageal cancer that has been assessed in the recent years and its potential as a target in therapy. This report summarizes the current knowledge about PI3K/AKT/mTOR pathway and its cross-talk with a focus on the value of targeting this pathway as a potential therapeutic target in the treatment of esophageal cancer.

scholarly journals PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay

2018 ◽  
Vol 48 (4) ◽  
pp. 396-399 ◽  
Author(s):  
Yasunari Sakamoto ◽  
Seri Yamagishi ◽  
Yoshinori Tanizawa ◽  
Masaomi Tajimi ◽  
Takuji Okusaka ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Therapeutic Target ◽  
Mtor Pathway ◽  
Potential Therapeutic Target ◽  
Tract Cancer

Abstract 4697: The PI3K/mTOR pathway is a potential therapeutic target in cancers with ARID1A mutations

2015 ◽  
Author(s):  
Suet-Yan Kwan ◽  
Daisy I. Izaguirre ◽  
Xuanjin Cheng ◽  
Suet-Ying Kwan ◽  
Yvonne TM Tsang ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Mtor Pathway ◽  
Potential Therapeutic Target

scholarly journals DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas

2021 ◽  
Vol 10 (3) ◽  
pp. 283-289
Author(s):  
M Ingenwerth ◽  
T Brandenburg ◽  
D Führer-Sakel ◽  
M Goetz ◽  
F Weber ◽  
...  
Keyword(s):  
Lymph Node ◽  
Neuroendocrine Tumors ◽  
Lymph Node Metastases ◽  
Therapeutic Target ◽  
Lymph Node Status ◽  
Potential Therapeutic Target ◽  
Medullary Thyroid ◽  
Thyroid Carcinomas ◽  
Node Metastases ◽  
Medullary Thyroid Carcinomas

Medullary thyroid carcinomas (MTC) are rare and aggressive neuroendocrine tumors of the thyroid. About 70% of MTC are sporadic; approximately 50% of those harbor somatic RET mutation. DLL3 is widely expressed in many neuroendocrine tumors and has been evaluated as a potential therapeutic target. Since stromal desmoplasia in sporadic MTC has been identified as a reliable predictor of aggressive behavior and development of lymph node metastases, a possible correlation of DLL3 expression with the presence of stromal desmoplasia was of particular interest. 59 paraffin-embedded samples of sporadic MTC with (44 cases) and without (15 cases) stromal desmoplasia and known lymph node status were included. DLL3 expression was determined by immunohistochemistry; no expression (0%), low expression (1–49%) and high expression (≥50%) were correlated with clinicopathological data. The proportion of DLL3 positivity was significantly correlated with both stromal desmoplasia (P < 0.0001) and lymph node metastases (P < 0.0001). MTC without stromal desmoplasia consistently lack DLL3 expression. This is the first study to focus on MTC regarding DLL3 expression and the relationship to various factors. Our results demonstrate that expression of DLL3 in MTC represents a reliable surrogate marker for stromal desmoplasia and lymph node metastases and might be an indicator for aggressive clinical behavior. DLL3 expression in ≥50% of tumor cells virtually excludes MTC without stromal desmoplasia. DLL3 was discussed as a potential therapeutic target in malignant tumors of other locations with positive immunohistochemical reaction and might therefore be a new therapeutic option in MTC, as well.

Sign in / Sign up

Export Citation Format

Share Document